论文部分内容阅读
心力衰竭(heart failure，HF)是各种心血管疾病发展的终末阶段，预后严重。虽然利钠肽(natriuretic peptides，NPs)仍然在HF的诊断及治疗中占有中心位置，但近几年新的生物标志物的发现为HF的病情评估提供了新的生命力。生长刺激表达基因2(growth stimulation expressed gene 2，ST2)蛋白和半乳糖凝集素(galectin，Gal)-3是近几年发现的新的生物标志物，ST2在心力衰竭的危险分层及预后评估中有独特优势，与NPs结合可以提高对HF的预后判断。Gal-3对HF的危险分层、预后，特别是短期结果预测具有独特的优势。“,”Heart failure(HF) is terminal stage in the development of various cardiovascular diseases with prognosis of severe.Although natriuretic peptide (NPs) still occupies the center in the diagnosis and treatment of HF, but the discovery of new biomarkers for condition evaluation of HF provides new vitality.growth stimulation expressed gene 2(ST2) and galectin(Gal)-3 are new biomarkers discovered in recent years.ST2 has unique advantages in risk stratification and prognosis assessment of heart failure, and its combination with NPs can improve the prognosis of heart failure.Gal-3 has unique advantages in risk stratification, prognosis and short-term outcome prediction of heart failure.